Literature DB >> 24837111

Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis.

Christopher Bogan1, Keith S Kaye1, Teena Chopra1, Kayoko Hayakawa1, Jason M Pogue2, Paul R Lephart3, Suchitha Bheemreddy1, Tsilia Lazarovitch4, Ronit Zaidenstein5, Federico Perez6, Robert A Bonomo7, Dror Marchaim8.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) isolation is associated with poor outcomes. The matched cohort study design enables investigation of specific role of resistance in contributing to patients' outcomes. Patients with CRE were matched to 3 groups: (1) patients with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL), (2) patients with carbapenem-susceptible non-ESBL Enterobacteriaceae, and (3) uninfected controls.
METHODS: Patients with CRE isolated at Detroit Medical Center (September 1, 2008, to August 31, 2009) were matched (1:1 ratio) to the 3 groups based on (1) bacteria type, (2) hospital/facility, (3) unit/clinic, (4) calendar year, and (5) time at risk (ie, from admission to culture). Multivariable logistic regression models for outcomes were constructed.
RESULTS: Ninety-one patients with CRE were enrolled. CRE isolation was not an independent predictor for in-hospital mortality in any of the models (ie, vs uncolonized controls, vs ESBL, vs non-ESBL Enterobacteriaceae, and vs all 3 non-CRE groups combined), despite high significance of association in bivariate analyses. CRE isolation was independently associated with deterioration in functional status [odds ratio, 9; P = .002] and being discharged to a long-term care facility after being admitted to the hospital from home [odds ratio, 13.7; P < .001].
CONCLUSION: Underlying condition and comorbidities are the principal factors responsible for in-hospital mortality in CRE infections; however, in-hospital mortality is not independently correlated to the offending pathogen. In addition, we found that the pathogen contributes significantly to patients' degree of morbidity.
Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CRE; Case control; Cohort study; KPC; Outcome; Risk factors

Mesh:

Substances:

Year:  2014        PMID: 24837111     DOI: 10.1016/j.ajic.2014.02.013

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  17 in total

1.  Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study.

Authors:  D R Giacobbe; V Del Bono; P Bruzzi; S Corcione; M Giannella; A Marchese; L Magnasco; A E Maraolo; N Pagani; C Saffioti; S Ambretti; C S Cardellino; E Coppo; F G De Rosa; P Viale; C Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-01       Impact factor: 3.267

Review 2.  Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).

Authors:  Dana R Bowers; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections.

Authors:  Q Wang; Y Zhang; X Yao; H Xian; Y Liu; H Li; H Chen; X Wang; R Wang; C Zhao; B Cao; H Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-11       Impact factor: 3.267

4.  Carbapenem-Resistant Enterobacteriaceae Acquired Before Liver Transplantation: Impact on Recipient Outcomes.

Authors:  Maristela Pinheiro Freire; Isabel C V S Oshiro; Ligia C Pierrotti; Patricia R Bonazzi; Larissa M de Oliveira; Alice T W Song; Carlos H Camargo; Inneke M van der Heijden; Flavia Rossi; Silvia F Costa; Luiz A C DʼAlbuquerque; Edson Abdala
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 5.  Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Authors:  Sandra S Richter; Dror Marchaim
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

6.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection and associated clinical outcomes.

Authors:  Guanqun Dai; Yanling Xu; Hui Kong; Weiping Xie; Hong Wang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

7.  The Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Colonization and Infection among Long-Term Acute Care Hospital Residents.

Authors:  John P Mills; Naasha J Talati; Kevin Alby; Jennifer H Han
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-12       Impact factor: 3.254

8.  Clonal dissemination of KPC-2-producing Klebsiella pneumoniae ST11 and ST48 clone among multiple departments in a tertiary teaching hospital in Jiangsu Province, China.

Authors:  Bing Gu; Ruru Bi; Xiaoli Cao; Huimin Qian; Renjing Hu; Ping Ma
Journal:  Ann Transl Med       Date:  2019-12

9.  β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Authors:  Rodrigo E Mendes; Mariana Castanheira; Leanne Gasink; Gregory G Stone; Wright W Nichols; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

10.  A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.

Authors:  Daniel J Livorsi; Margaret L Chorazy; Marin L Schweizer; Erin C Balkenende; Amy E Blevins; Rajeshwari Nair; Matthew H Samore; Richard E Nelson; Karim Khader; Eli N Perencevich
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-24       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.